89bio Inc

89bio — Investor Presentation (April 2025)

74 slides from 89bio's investor presentation, Apr 9, 2025

  1. Slide 1: Powerful Science, Meaningful Medicines, Changing Lives

    Exhibit 99.1 Powerful Science Meaningful Medicines Changing Lives Nasdaq: ETNB April 2025

  2. Slide 2: Disclaimers

    Disclaimers This presentation contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Other than statements of historical facts, all statements included in

  3. Slide 3: Corporate Highlights

    Corporate Highlights Pegozafermin (long-acting FGF21) Potential Best-in-class profile Well-positioned for targets three significant with robust fibrosis benefit and commercial success market opportunities favorable tolerability/safety FGF21 is the leading mechanism of • Reversal of fibrosis and cirr

  4. Slide 4: Advancing Pegozafermin Through Late-Stage Clinical Development

    Advancing Pegozafermin Through Late-Stage Clinical Development ANTICIPATED KEY INDICATION TRIAL PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MILESTONES Histology MASH * Phase 3 trial in F2/F3: Histology & Outcomes – Ongoing data 1H 2027 Breakthrough Therapy & Histology PRIME * Phase 3 trial in F4: Histology

  5. Slide 5: Pegozafermin is an FGF21 Analog Optimally Engineered to Balance Efficacy and Long Dosing Interval

    Pegozafermin is an FGF21 Analog Optimally Engineered to Balance Efficacy and Long Dosing Interval glycoPEG(20kD) FGF21 Pegozafermin EC (nM) EC (nM) 50 50 Strong and flexible linker RECEPTOR Mean ± S.D. Mean ± S.D. (glycoPEGylation technology) Position 182 KLB nd nd KLB/FGFR1 4.5 ± 1.0 0.3 ± 0.07 N-t

  6. Slide 6: Global Manufacturing Strategy Provides Resilience and Flexibility

    Global Manufacturing Strategy Provides Resilience and Flexibility Resilient and diversified supply chain with alternative CDMOs for each step in the supply chain mitigates against macroeconomic and geopolitical environment changes Northway Biotech (“BTPH”) BiBo Biopharma Engineering • EU-based CDMO

  7. Slide 7: Opportunity in MASH

    Opportunity in MASH

  8. Slide 8: Pegozafermin Offers Potential Best-in-Class Therapeutic for Advanced MASH

    Pegozafermin Offers Potential Best-in-Class Therapeutic for Advanced MASH REDUCES LIVER FAT FAVORABLE TOLERABILITY & IMPROVES REVERSES LIVER FIBROSIS RESOLVES MASH CONVENIENT DOSING INSULIN to improve patient RESISTANCE persistence and compliance IMPROVES DYSLIPIDEMIA * If approved 7

  9. Slide 9: ENLIVEN Phase 2b Trial Evaluated Weekly and Every-Two-Week Dosing in Non-cirrhotic Patients

    ENLIVEN Phase 2b Trial Evaluated Weekly (QW) and Every-Two-Week (Q2W) Dosing in Non-cirrhotic Patients BLINDED PRIMARY ENDPOINTS MAIN STUDY EXTENSION PHASE (24 weeks) (24 weeks) • ≥1-stage fibrosis improvement 1 with no worsening of MASH Placebo (QW or Q2W) PLACEB PLO* ACEBO (QWQ2 orW Q2W) • MASH re

  10. Slide 10: Pegozafermin Demonstrated Statistical Significance on Fibrosis Improvement at 30mg QW and 44mg Q2W

    WEEK 24 Pegozafermin Demonstrated Statistical Significance on Fibrosis Improvement at 30mg QW and 44mg Q2W Dose Rigorous Biopsy Reading Methodology Independent 3-reader consensus methodology, that minimizes placebo response rate and more accurately measures drug effect Fibrosis Improvement Without W

  11. Slide 11: Comparative Clinical Data in Non-Cirrhotic (F2/F3) Patients

    Comparative Clinical Data in Non-Cirrhotic (F2/F3) Patients ≥1 Stage Fibrosis Improvement with No Worsening of MASH 1 Pegozafermin Efruxifermin Efimosfermin Survodutide Rezdiffra Tirzepatide Denifanstat VK2809 Semaglutide FGF21 FGF21 FGF21 GLP-1/Glucagon TR-β Agonist GLP-1/GIP FASN TR-β Agonist GLP-

  12. Slide 12: Relative Risk: A Better Method for Cross-Trial Effectiveness Comparisons

    Relative Risk: A Better Method for Cross-Trial Effectiveness Comparisons As Presented by Michael Charlton MD at MASH-TAG Jan 10, 2025 RELATIVE RISK: The comparative probability of achieving the primary efficacy endpoint. Used to estimate the strength of 1 association between treatment and an outcome

  13. Slide 13: Relative Risk: Pegozafermin Outperforms Other Drugs in F2/F3 Patients

    Relative Risk: Comparative Clinical Data in Non-Cirrhotic (F2/F3) Patients Pegozafermin Outperforms Other Drugs Based on Relative Risk In absence of H2H studies, Relative Risk, or drug response as a multiple of placebo, offers robust window for cross-trial comparisons by controlling for variability

  14. Slide 14: Pegozafermin Differentiates as a Leading Therapy for F2-F3 MASH Based on Highest SUCRA Score

    Pegozafermin Differentiates as a Leading Therapy for F2-F3 MASH Based on the Highest SUCRA Score (Hepatology Journal) COMPARISON OF PHARMACOLOGICAL THERAPIES IN MASH FOR FIBROSIS REGRESSION AND MASH RESOLUTION Data Sources 29 randomized controlled trials 9,234 Patients with MASH Source: Souza, Mathe

  15. Slide 15: Pegozafermin Demonstrated Statistical Significance on MASH Resolution at All Doses

    WEEK 24 Pegozafermin Demonstrated Statistical Significance on MASH Resolution at All Doses MASH Resolution Without Worsening of Fibrosis at Week 24 p=0.0005 p=0.0009 50% p<0.0001 40% 37% 30% 26% 23% 20% 35% 24% 21% 10% 2% 0% Placebo 15mg QW 30mg QW 44mg Q2W n=61 n=14 n=66 n=51 * Relative Risk 1.0 18

  16. Slide 16: Significance on Combined Endpoint of Fibrosis Improvement and MASH Resolution

    WEEK 24 Pegozafermin Demonstrated Statistical Significance on the Combined Endpoint of Fibrosis Improvement and MASH Resolution Both Fibrosis Improvement and ≥2-Point Improvement in NAS and MRI-PDFF MASH Resolution at Week 24 Response and ALT Response 30% 80% *** 60% *** 60% *** 20% 52% 20% *** 14%

  17. Slide 17: Robust Liver Fat Reduction with High Responder Rates by MRI-PDFF

    WEEK 24 Pegozafermin Demonstrated Robust Liver Fat Reduction with High Responder Rates by MRI-PDFF 1 Mean Relative Reduction in Liver Fat vs Baseline Patients Achieving ≥30% and ≥50% Reduction in 2 at Week 24 Hepatic Fat Fraction Versus Baseline Placebo 30mg QW 44mg Q2W N=48 N=49 N=35 100% 0% -10% 8

  18. Slide 18: Significant Improvements in Markers of Liver Injury/Inflammation (ALT and AST)

    WEEK 24 Pegozafermin Demonstrated Significant Improvements in Markers of Liver Injury/Inflammation (ALT and AST) Mean Relative Reduction in ALT vs Mean Relative Reduction in AST vs Baseline at Week 24 Baseline at Week 24 Placebo 30mg QW 44mg Q2W Placebo 30mg QW 44mg Q2W n=61 n=66 n=51 n=61 n=66 n=51

  19. Slide 19: Significant Reductions in Non-Invasive Markers of Liver Inflammation and Fibrosis

    WEEK 24 Pegozafermin Demonstrated Significant Reductions in Non-Invasive Markers (NITs) of Liver Inflammation and Fibrosis cT1 - Absolute Change from VCTE - Absolute Change from FAST - Percent Change from Baseline at Week 24 (ms) Baseline at Week 24 (kPa) Baseline at Week 24 0 0% 0.8 0.5 -6 -6% -20

  20. Slide 20: Significant Improvements on Non-Invasive Markers for Fibrosis

    WEEK 24 Pegozafermin Demonstrated Significant Improvements on Non- Invasive Markers (NITs) for Fibrosis ELF - Absolute Change from FIB-4 - Absolute Change from PRO-C3 - Percent Change from Baseline at Week 24 Baseline at Week 24 Baseline at Week 24 0.3 0.2 6% 0.2 0.1 5% 0.1 0.0 -5% -0.1 -0.2 -15% -0

  21. Slide 21: Long-term Treatment Results in Sustained Week 48 Improvements Across Liver NITs

    WEEK 24 Long-term Treatment with Pegozafermin Results in Sustained WEEK 48 Improvements over a Wide Range of Liver NITs Placebo Placebo 30mg QW 30mg QW 44mg Q2W 44mg Q2W Week 24 Week 48 Week 24 Week 48 Week 24 Week 48 (n=42) (n=35) (n=66) (n=50) (n=51) (n=45) MRI-PDFF -6% -11% -56% -60% -60% -47% AL

  22. Slide 22: Pegozafermin Offered Additive Benefits to GLP-1 Therapy Through Week 48

    GLP1 Pegozafermin Offered Additive Benefits to GLP-1 Therapy in Patients with MASH through Week 48 KEY RESULTS BACKGROUND • 37 patients in ENLIVEN were on GLP-1 therapy Pegozafermin on top of GLP-1 therapy showed the at baseline – 25 received pegozafermin, 12 following versus GLP-1 plus placebo at w

  23. Slide 23: Greater Benefits on Fibrosis Markers with Pegozafermin plus GLP-1 at Week 24

    WEEK 24 Greater Benefits on Fibrosis Markers Were Observed with Pegozafermin GLP1 vs. Placebo in Patients on Background GLP-1 Therapy at Week 24 ALT (%) VCTE (kPa) ELF Score Pro-C3 (%) 0.5 40% 0% 0.0 +0.3 +26% 0.3 -0.5 -0.4 -11% 20% -1.0 0.1 -25% -1.5 -0.1 0% -2.0 -0.3 -38% -2.1 -0.4 -50% -0.5 -20%

  24. Slide 24: Greater Benefits on Metabolic Markers with Pegozafermin plus GLP-1 at Week 24

    WEEK 24 Greater Benefits on Metabolic Markers Were Observed with Pegozafermin GLP1 vs. Placebo in Patients on Background GLP-1 Therapy at Week 24 HbA1c Triglycerides (%) MRI-PDFF (%) Adiponectin (%) 0% 0 0% 40% 0% 33% -0.1 -20% -10% 30% -0.1 -0.2 -28% 20% -40% -20% -0.3 10% -60% -30% -54% 4% -0.4 -2

  25. Slide 25: Promising Profile in Patients with Compensated MASH Cirrhosis (F4)

    F4 Pegozafermin Offers a Promising Profile in Patients with Compensated MASH Cirrhosis (F4) KEY RESULTS BACKGROUND • ENLIVEN enrolled 14 MASH stage F4 patients of • 45% of pegozafermin-treated patients had fibrosis which 12 patients* had follow-up biopsies at improvement ≥1 stage without worsening o

  26. Slide 26: Fibrosis Improvement Without Worsening of MASH in 45% of F4 Patients

    WEEK 24 Pegozafermin Achieved Fibrosis Improvement Without Worsening F4 of MASH in 45% of Patients with F4 Fibrosis at Baseline Fibrosis Improvement ≥1 Stage Without Worsening of MASH 50% 45% • Pegozafermin treatment led to fibrosis improvement ≥1 40% stage in 9/11 treated patients (82%) 30% • Pegoz

  27. Slide 27: NIT Results over Weeks in F4 Patients From ENLIVEN

    WEEK 24 NIT Results over 48 Weeks in F4 Patients From ENLIVEN WEEK 48 Demonstrated Consistent Benefit F4 PGZ-Treated Patients (n=12) Parameter 24 weeks 48 weeks Liver Fibrosis and Inflammation ELF (units) -0.3 -0.5 FAST -46% -42% VCTE (kPa) -2.7 -1.1 Pro-C3 -5% -20% FIB-4 -11% -16% Liver Injury ALT

  28. Slide 28: Pegozafermin Was Well Tolerated Across All Patients in ENLIVEN

    WEEK 48 Pegozafermin Was Well Tolerated Across All Patients In ENLIVEN Most TEAEs were Grade 1 and Grade 2 Drug-related TEAEs in ≥10% of patients Through 48 Weeks Placebo 15mg QW 30mg QW 44mg Q2W Preferred Term (n=50) (n=21) (n=72) (n=57) Diarrhea 3% 24% 17% 9% Nausea 1% 14% 21% 18% Injection site e

  29. Slide 29: No Clinically Meaningful Bone Effect in the Pegozafermin Program

    No Clinically Meaningful Bone Effect in the Pegozafermin Program Based on Bone Biomarker, Bone Mineral Density, and Fracture Risk to Date 1 • No clinically meaningful or statistically significant bone biomarker or DXA changes vs. placebo through 48 weeks of treatment with 30mg QW or 44mg Q2W dose in

  30. Slide 30: ENLIGHTEN-Fibrosis: Phase 3 Trial in MASH with Advanced Fibrosis (F2-F3)

    ENLIGHTEN-Fibrosis: Phase 3 trial in MASH with Advanced Fibrosis (F2-F3) OUTCOMES HISTOLOGY PORTION Placebo Pegozafermin 30mg QW Pegozafermin 44mg Q2W B B B Co-Primary Endpoints Up to B Liver Biopsy at Week 52 Month 36 1 HISTOLOGY FOR ACCELERATED APPROVAL OUTCOMES FOR FULL APPROVAL • Primary Endpoin

  31. Slide 31: ENLIGHTEN-Fibrosis: Potential for Success on Histology and Clinical Outcomes

    ENLIGHTEN-Fibrosis: Potential for success on both histology and clinical outcomes for F2/F3 MASH HISTOLOGY OUTCOMES • FGF21 analogs have demonstrated robust • Build on strong fibrosis regression and NIT fibrosis regression at both week 24 and over data demonstrated from ENLIVEN longer time frames •

  32. Slide 32: ENLIGHTEN-Cirrhosis: Phase 3 Trial in Compensated Cirrhosis (F4)

    ENLIGHTEN-Cirrhosis: Phase 3 Trial in Compensated Cirrhosis (F4) OUTCOMES HISTOLOGY PORTION Placebo Pegozafermin 30mg QW B B Primary Endpoint B Liver Biopsy at 24 Months 1 HISTOLOGY FOR ACCELERATED APPROVAL OUTCOMES FOR FULL APPROVAL • Primary Endpoint: Clinical outcomes composite to support full •

  33. Slide 33: ENLIGHTEN-Cirrhosis: Potential for Success on Histology and Outcomes

    ENLIGHTEN-Cirrhosis: Potential for Success on Histology and Outcomes HISTOLOGY OUTCOMES • Build on strong fibrosis regression and • FGF21 analogs have demonstrated clear NIT data from ENLIVEN benefit on fibrosis regression in F4 patients • Enroll/select additional patients with the right profile to

  34. Slide 34: Potential to Address Substantial Needs in MASH with Advanced Fibrosis and Cirrhosis

    Potential to Address Substantial Needs in MASH with Advanced Fibrosis and Cirrhosis Large patient population with significant health risks • ~15M patients in the US are expected to have MASH (F2-F4) by 2035; similar number in EU 1 – F2-F3 and F4 prevalence may reach ~10.7M and ~3.6M respectively, ne

  35. Slide 35: Pegozafermin Positioned to Address Advanced MASH

    Pegozafermin Positioned to Address Advanced MASH FIBROSIS STAGING F1 F2 F3 F4 (Compensated) LOW Risk Staging based on: MEDIUM • Fibrosis Progression • Liver Events HIGH • CV Events VERY HIGH Improve Glycemic Control / Improve Dyslipidemia / Reduce Weight Resolve Steatohepatitis Primary Treatment Pre

  36. Slide 36: Advanced MASH (F2/F3) Represents a Significant Market

    Advanced MASH (F2/F3) Represents a Significant Market F2/F3 F2/F3 Prevalence: With and Without Incretin Effect Eligible Pool of Diagnosed Patients 3 20 ~1.8M PATIENTS 17% OF PATIENTS ~13.5M 15 PATIENTS 2 5% CAGR 12% CAGR ~530K 10 PATIENTS 7% OF PATIENTS 3% CAGR 1 ~10.7M PATIENTS 5 2024 2035 2024 203

  37. Slide 37: Market Opportunity in Compensated F4 Patients Expected to Grow

    Market Opportunity in Compensated F4 Patients Expected to Grow F4 F4 Eligible Pool of Diagnosed Patients Prevalence: With and Without Incretin Effect 6 ~820K PATIENTS DIAGNOSED 23% ~4.2M 1.0 DIAGNOSED PATIENTS 4 0.8 7% CAGR 14% CAGR ~190K PATIENTS DIAGNOSED 0.5 5% CAGR 9% ~3.6M DIAGNOSED 2 PATIENTS

  38. Slide 38: Potential Usage in Multiple Settings with GLP-1

    Pegozafermin – Potential Usage in Multiple Settings with GLP-1 Based on Treatment History, Fibrosis Stage and Comorbidities Future Treatment Decision-making PRIOR GLP-1 in MASH Patients ILLUSTRATIVE EXPOSURE? Yes, ongoing Yes, discontinued No Does patient have Degree of fibrosis? Why did patient dis

  39. Slide 39: Expected to Garner Significant Market Share in F3 Patients

    Pegozafermin Expected to Garner Significant Market Share In F3 Patients F3 EXPECTED PRESCRIBING AMONGST HEP/GI PHYSICIANS (% treated MASH patients) FGF21s garner ~45% market THR-β rd share, with ~2/3 gained by PGZ 28% • PGZ benefit/risk profile (driven by favorable tolerability/safety) and GLP-1 (mo

  40. Slide 40: Expected to Garner Significant Market Share in Compensated F4 Patients

    Pegozafermin Expected to Garner Significant Market Share In Compensated F4 Patients ^ Compensated F4 EXPECTED PRESCRIBING AMONGST HEP/GI PHYSICIANS (% treated MASH patients) FGF21s garner ~60% market THR-β share, with ~60% gained by PGZ GLP-1 (mono) 10% • PGZ benefit/risk profile (driven by 16% favo

  41. Slide 41: Tolerability/Safety and Dosing Convenience Expected to be Key Differentiators

    Tolerability/Safety and Dosing Convenience Expected to be Key Differentiators for Pegozafermin in the Commercial Marketplace • Key drivers of patient compliance and persistency include drug tolerability/safety and convenience, especially in asymptomatic disease indications 1 – GI Adverse events are

  42. Slide 42: Every Two-Week Dosing Provides Opportunity to Optimize Therapy to Patient Preference

    Every Two-Week Dosing Provides Opportunity for Physicians to Optimize Therapy to Patient Preference Preference of Every-Two-Week Injections Over Weekly Injections 63% 36.7% Prefer or strongly prefer 18.7% 26.7% 10.0% 8.0% None Minimal Moderate Preferred Strong Source: Primary market research with 15

  43. Slide 43: Opportunity in Severe Hypertriglyceridemia (SHTG)

    Opportunity in Severe Hypertriglyceridemia (SHTG)

  44. Slide 44: Pegozafermin Could Offer an Important New Treatment Option for SHTG

    Pegozafermin Could Offer an Important New Treatment Option for SHTG Topline results expected in 1Q 2026 Large growing patient population with significant health risks; overlap with MASH patient population • Increasing TG levels increase risk of acute pancreatitis, cardiovascular disease and all-caus

  45. Slide 45: Phase 2 SHTG Trial Design

    – Phase 2 SHTG Trial Design KEY INCLUSION CRITERIA 8 Weeks• TG ≥500mg/dL and ≤2,000mg/dL PLACEBO (n=18) • Background therapy: statins and/or prescription fish oil and/or fibrates OR none 9mg QW Pegozafermin (n=16) PRIMARY ENDPOINT 18mg QW Pegozafermin (n=17) • Primary endpoint: % Change in TGs from

  46. Slide 46: Pegozafermin Significantly Reduced Triglycerides Across All Dose Groups

    Pegozafermin Significantly Reduced Triglycerides Across All Dose Groups Median % Change in Triglycerides from Baseline at Week 8 QW Q2W Placebo 9mg 18mg 27mg 36mg -10% -12% Q1; Q3: [-23.22; 7.88] -30% * -36% Q1; Q3: [-62.39; -10.92] -50% *** *** -56% -57% Q1; Q3: [-67.60; -39.85] Q1; Q3: [-64.73; -4

  47. Slide 47: Significant Decrease in Triglycerides on Top of Background Therapy

    Pegozafermin Showed Significant Decrease in Triglycerides on Top of Background Therapy Median % Change in Triglycerides from Baseline at Week 8 Not On Background Therapy On Background Therapy QW Q2W QW Q2W Placebo 9mg 18mg 27mg 36mg Placebo 9mg 18mg 27mg 36mg n=6 n=8 n=8 n=6 n=8 n=11 n=8 n=9 n=10 n=

  48. Slide 48: Significant Decrease in Triglycerides at Different Threshold Levels

    Pegozafermin Showed Significant Decrease in Triglycerides at Different Threshold Levels TG Normalization TG Reduction ≥50% from baseline Responders (<500 mg/dL) (<150mg/dL, <200mg/dL) *** 60% 100% 80% 75% *** 80% 44% 80% 60% 40% * 60% 31% 40% 40% 29% 20% 20% 20% 6% <150 <200 0% mg/dL mg/dL 0% 0% 0%

  49. Slide 49: Clinically Meaningful Improvements in Key Markers of CV Risk for SHTG

    Pegozafermin Demonstrated Clinically Meaningful Improvements in Key Marker of CV Risk for SHTG Mean % Change from Baseline at Week 8 Mean % Change from Baseline at Week 8 Non-HDL-C Apo-B Q2W QW Q2W QW Placebo 9mg 18mg 27mg 36mg Placebo 9mg 18mg 27mg 36mg Baseline (mg/dL): 218 216 203 202 215 Baselin

  50. Slide 50: Significant Improvement on Key Co-morbidities for SHTG Patients

    Pegozafermin Demonstrated Significant Improvement on Key Co-morbidities for SHTG Patients Mean Relative Reduction in Liver Fat vs Absolute Change in HbA1c at Week 8 Baseline at Week 8 Patients with Baseline HbA1c ≥6.5% Placebo PGZ pooled Placebo 27mg QW n=6 n=17 n=6 n=9 0% 0 -5% -0.1 -20% -0.2 -0.2

  51. Slide 51: Favorable Safety/Tolerability Profile in Phase 2 Trial

    Pegozafermin Demonstrated Favorable Safety/Tolerability Profile in Phase 2 Trial • Pooled pegozafermin treatment related Adverse Events (AEs) observed in ≥7.5% of patients were: – Nausea (10%), diarrhea (9%) and injection site reaction (9%) vs placebo (0%) – All Gastrointestinal (GI) AEs were Grade

  52. Slide 52: Phase 3 ENTRUST Trial Design

    Phase 3 ENTRUST Trial Design KEY INCLUSION CRITERIA • TG ≥500mg/dL and 52 WEEKS ≤2,000mg/dL • Stable background lipid Placebo QW (n=90) modifying therapy* PRIMARY ENDPOINT Pegozafermin 20mg QW (n=135) • Percent change from baseline in fasting TGs at Week 26 vs. Pegozafermin 30mg QW (n=135) placebo,

  53. Slide 53: SHTG Represents a Large Population with High Unmet Need

    SHTG Represents a Large Population with High Unmet Need Prevalence in US PREVALENCE Co-morbidity SHTG UP TO 4 MILLION population Fatty Liver Disease Up to 100% (NAFLD) DIAGNOSED ~2.8 MILLION Type 2 Up to 70% diabetes/Prediabetes Dyslipidemia Up to 65% UN-TREATED DRUG TREATED ~1.1 MILLION ~1.7 MILLIO

  54. Slide 54: Pegozafermin Delivers on Key Attributes for Successful SHTG Therapy

    Pegozafermin Delivers on Key Attributes for Successful SHTG Therapy MINOR INFLUENCE MODEST INFLUENCE MAJOR INFLUENCE Hierarchy of Attributes for SHTG Therapy RoA/Dosing Clinical Outcomes Safety/Tolerability Metabolic Endpoints TG Endpoints • RoA and dosing were • Physicians noted that • Lesser impac

  55. Slide 55: Similar TG Effects and Added Metabolic Benefits vs APO-C3 Inhibitor

    Pegozafermin has Similar TG Effects and Added Metabolic Benefits with No Increase in LDL-C when Compared to APO-C3 Inhibitor Pegozafermin Plozasiran (ARO-APO-C3) 1 2 ENTRIGUE SHASTA-2 Endpoint 27mg QW placebo-adjusted 25mg Q12W placebo-adjusted TG -53% -53% % Patients with TG<500 46% 39% Liver fat b

  56. Slide 56: Corporate Highlights

    Corporate Highlights Pegozafermin (long-acting FGF21) Potential Best-in-class profile Well-positioned for targets three significant with robust fibrosis benefit and commercial success market opportunities favorable tolerability/safety FGF21 is the leading mechanism of • Reversal of fibrosis and cirr

  57. Slide 57: Appendix

    Appendix

  58. Slide 58: Experienced Management Team Positions 89bio for Success

    Experienced Management Team Positions 89bio for Success Ryan Martins Rohan Palekar Hank Mansbach, MD Francis Sarena Quoc Le-Nguyen Teresa Perney, PhD CTO CR&QO CEO CMO COO CFO 20+ years biopharma 20+ years biotech and CEO, CCO experience 20+ years biopharma C-suite biotech executive CFO experience a

  59. Slide 59: Pegozafermin Exhibits Highly Potent FGF Receptor Agonism

    Pegozafermin Exhibits Highly Potent FGF Receptor Agonism FGFR2 FGFR3 FGFR4 FGFR1 2000 3000 BIO89-100 BIO89-100 BIO89-100 BIO89-100 2600 5500 FGF21 FGF21 1800 FGF21 FGF21 2600 2200 4500 1600 2200 1400 1800 3500 1800 1200 1400 2500 1400 1000 1000 1500 800 1000 600 600 500 600 0.0001 0.1 100 0.0001 0.1

  60. Slide 60: ENLIVEN Baseline Characteristics Well Balanced Across Dose Groups

    ENLIVEN Baseline Characteristics Well Balanced Across Dose Groups Parameter Placebo 15mg QW 30mg QW 44mg Q2W Total Mean or % (n=71) (n=21) (n=73) (n=57) (n=222) Age (years) 56 55 55 55 56 Female 55% 43% 69% 65% 61% 2 BMI (kg/m ) 38 38 35 36 37 Type 2 Diabetes 69% 86% 62% 61% 66% Fibrosis Stage (% F3

  61. Slide 61: ENLIVEN Patient Disposition and Analysis Sets

    ENLIVEN Patient Disposition and Analysis Sets DOSED Safety Analysis Set Ineligible per 3-panel read N=219 • Stage F1 (n=7) • Stage F4 (n=14) • Stage F2/F3 but NAS <4 (n=6) F2/F3, NAS≥4 N=192 Full Analysis Set (FAS) Placebo 15mg QW 30mg QW 44mg Q2W n=61 n=14 n=66 n=51 Extension Placebo 30mg QW Phase

  62. Slide 62: ENLIVEN Used Objective Biopsy Reading Methodology

    ENLIVEN Used Objective Biopsy Reading Methodology Designed to Reduce Histology Scoring Biases and Variability ALL BIOPSIES SCORED INDEPENDENTLY • Pathologists underwent AND SEPARATELY protocol-specific harmonization training Pathologist Pathologist Pathologist before and during trial #1 #2 #3 • Path

  63. Slide 63: Learnings from the Obeticholic Acid MASH Program: Single Central Reader vs 3-Panel Consensus

    Learnings from the Obeticholic Acid MASH Phase 3 Program: Comparison of Single Central Reader vs. 3-Panel Consensus Improvement of Fibrosis by ≥ 1 Stage without Worsening Resolution of MASH with No Worsening of Liver Fibrosis MASH OBSERVATIONS: • Placebo response for MASH resolution is >2 fold highe

  64. Slide 64: Sensitivity Analysis Treating Missing Histology Data as Non-Responder

    Sensitivity Analysis Treating Missing Histology Data as Non-Responder Confirms Robustness of Primary Efficacy Results Fibrosis Improvement and MASH Resolution Missing Data = Non-Responder n=192, Week 24 30mg QW 44mg Q2W Fibrosis improvement without worsening of MASH Effect Size (placebo-adjusted) 15

  65. Slide 65: Meaningful Reductions in HbA1c (ENLIVEN)

    WEEK 24 Pegozafermin Demonstrated Meaningful Reductions in HbA1c (ENLIVEN) Change in HbA1c from Baseline at Week 24 Total Population Baseline HbA1c ≥6.5% Placebo 30mg QW 44mg Q2W Placebo 30mg QW 44mg Q2W n=61 n=66 n=51 n=31 n=32 n=25 0.0 0.0 0.0 0.0 -0.1 -0.1 -0.2 -0.2 -0.3 -0.2 -0.4 -0.3 -0.4 * -0.

  66. Slide 66: Meaningful Changes in Serum Lipids (ENLIVEN)

    WEEK 24 Pegozafermin Demonstrated Meaningful Changes in Serum Lipids (ENLIVEN) Percent Change in Serum Lipids from Baseline at Week 24 Triglycerides Non-HDL Cholesterol HDL Cholesterol 0% 0% 0% 20% *** 14% -6% -10% 10% * -10% 6% -20% 0% -7% -7% -3% *** -27% -30% -10% -10% Placebo 30mg QW 44mg Q2W Pl

  67. Slide 67: Independent Patient Confirmation of Pegozafermin Treatment Effect

    CROSSOVER Independent Patient Confirmation of Pegozafermin Treatment Effect Placebo Patients Showed Robust Benefits Upon Crossing Over to Pegozafermin Change from Baseline Main Study Extension Phase Parameter Placebo 30mg QW n=19 n=19 MRI-PDFF -21% -63% ALT -2% -32% AST -2% -31% PRO-C3 +8% -17% FAST

  68. Slide 68: Sustained Benefits on Fibrosis Markers with Pegozafermin plus GLP-1 at Week 48

    WEEK 48 Sustained Benefits on Fibrosis Markers Were Observed with Pegozafermin GLP1 vs. Placebo in Patients on Background GLP-1 Therapy at Week 48 (ENLIVEN) ELF Score FAST (%) Pro-C3 (%) ALT (%) 0% 0 0% 0% 0 -5% -20% -0.2 -20% -15% -10% -9% -15% -40% -40% -0.4 * -43% -20% -44% -19% -0.5 -52% -60% -0

  69. Slide 69: Sustained Benefits on Metabolic Markers with Pegozafermin plus GLP-1 at Week 48

    WEEK 48 Sustained Benefits on Metabolic Markers Were Observed with Pegozafermin GLP1 vs. Placebo in Patients on Background GLP-1 Therapy at Week 48 (ENLIVEN) MRI-PDFF (%) Triglycerides (%) LDL-C (%) Placebo + GLP-1 PGZ + GLP-1 Placebo + GLP-1 PGZ + GLP-1 Placebo + GLP-1 PGZ + GLP-1 n=8 n=17 n=8 n=18

  70. Slide 70: Consistent Benefit in Fibrosis Improvement Across Prespecified Subgroups

    Pegozafermin Showed Consistent and Significant Benefit in Achieving Fibrosis Improvement Across Prespecified Subgroups Pegozafermin 30mg QW Pegozafermin 44mg Q2W Proportion Achieving Fibrosis Improvement Proportion Achieving Fibrosis Improvement BL T2DM: Yes BL T2DM: Yes BL T2DM: No BL T2DM: No BL F

  71. Slide 71: Comparative Tolerability Profile of FGF21 Analogs in MASH

    Comparative Tolerability Profile of FGF21 Analogs in MASH (Week 24 data) GlycoPEGylated Fusion Proteins Pegozafermin (PGZ) Efruxifermin (EFX) Efimosfermin 24 weeks 24 weeks 24 weeks 30mg QW 44mg Q2W 28mg QW 50mg QW 300mg Q4W n=72 n=57 n=40 n=43 N=43 Adverse Events (key terms) 1 Diarrhea 17% 9% 35% 3

  72. Slide 72: Pegozafermin Expected to be Best-in-Class in FGF21 Category Based on Clinical Data

    Pegozafermin Expected to be Best-in-Class in the FGF21 Category Based on Clinical Data Showing Favorable Tolerability/Safety Pegozafermin Efruxifermin Efimosfermin CLINICAL DATA N=222; 3 doses tested N= 128; 2 doses tested N=84; 1 dose tested Phase 2 design (F2-F3) 60% F3 patients 66% F3 patients 44

  73. Slide 73: Expected to be Best-in-Class in FGF21 Category Based on Other Properties

    Pegozafermin Expected to be Best-in-Class in the FGF21 Category Based on Other Properties Pegozafermin Efruxifermin Efimosfermin FGF21 PROPERTIES Structure Glycopegylated FGF21 FGF21-Fc Fusion FGF21-Fc Fusion 90-95 KDa Molecular Weight 40 KDa 92 KDa FGF21 moles delivered (high dose) 1.5 mmol (per we

  74. Slide 74: Fold Change vs. Placebo for Fibrosis Improvement (Relative Risk)

    Fold Change vs. Placebo for Fibrosis Improvement (Relative Risk) No Worsening of MASH: F1-3 in Phase 2b/3 As Presented by Michael Charlton MD at MASH-TAG Jan 10, 2025 4 Peg REALM OF HOPE FGF21 OBSERVED BIOLOGICAL CEILING OF HEPATIC FIBROSIS REGRESSION Fc FGF21 3 GLP/GCG Fc FGF21 FASNi FXR 2 PPAR-δ T

89bio — Investor Presentation (April 2025) on 6ix